Farnesol

Farnesol

SCHEMBL6422271

CC(C)=CCC/C(C)=C/CCC(C)=CCO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 1.00
MAPT P10636 2/20 1.00
MEN1 O00255 2/20 1.00
CYP3A4 P08684 2/20 1.00
ALOX15 P16050 2/20 1.00
ALDH1A1 P00352 1/20 1.00
UGT1A1 P22309 1/20 1.00
SQLE Q14534 7/20 0.71
KDM4E B2RXH2 1/20 0.59
ICMT O60725 1/20 0.57
FNTA P49354 1/20 0.53
FNTB P49356 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Geranylgeraniol SCHEMBL127330 1.00 KMT2A (1.00) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL7944378 1.00 KMT2A (1.00) KMT2AMAPTMEN1CYP3A4ALOX15
Farnesol SCHEMBL17633996 1.00 KMT2A (1.00) KMT2AMAPTMEN1CYP3A4ALOX15
Geranylgeraniol SCHEMBL17557239 1.00 KMT2A (1.00) KMT2AMAPTMEN1CYP3A4ALOX15
Geranylgeraniol SCHEMBL16664300 1.00 KMT2A (1.00) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL4717874 1.00 KMT2A (1.00) KMT2AMAPTMEN1CYP3A4ALOX15
Geranylgeraniol SCHEMBL23814969 1.00 KMT2A (1.00) KMT2AMAPTMEN1CYP3A4ALOX15
Solanesol SCHEMBL4762223 1.00 KMT2A (1.00) KMT2AMAPTMEN1CYP3A4ALOX15
Farnesol SCHEMBL7546574 1.00 KMT2A (1.00) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL16664315 1.00 KMT2A (1.00) KMT2AMAPTMEN1CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0731160-B1 Parfume containing (3S)-(6E)-2,3-dihydrofarnesol TAKASAGO PERFUMERY CO LTD (JP) 2002-06-12 EP claimed
US-5753610-A MICROBIOCIDE TAKASAGO INTERNATIONAL CORPORATION (JP) 1998-05-19 US claimed
EP-0731160-A2 Perfume containing (6E)-2,3-dihydrofarnesol Takasago International Corporation (JP) 1996-09-11 EP claimed
JP-8245979-A None JP disclosed
US-20240209132-A1 COUPLING OF 2,3,5-TRIMETHYLHYDROQUINONE AND UNSATURATED ALCOHOLS DSM IP ASSETS B.V. (NL) 2024-06-27 US disclosed
EP-4330244-A1 COUPLING OF 2,3,5-TRIMETHYLHYDROQUINONE AND UNSATURATED ALCOHOLS DSM IP Assets B.V. (NL) 2024-03-06 EP disclosed
CN-117203193-A Coupling of 2,3, 5-trimethylhydroquinone with unsaturated alcohols 帝斯曼知识产权资产管理有限公司 2023-12-08 CN disclosed
US-11802100-B2 Olefins and methods for making the same Amyris, Inc. (US) 2023-10-31 US disclosed
CN-109071480-A Solid forms of (-) -ambrox formed by bioconversion of homofarnesol in the presence of a biocatalyst 奇华顿股份有限公司 2018-12-21 CN disclosed
US-9862906-B2 Base oils and methods for making the same Amyris, Inc. (US) 2018-01-09 US disclosed
US-9464257-B2 Fragrance composition TAKASAGO INTERNATIONAL CORPORATION (JP) 2016-10-11 US disclosed
US-5753610-A MICROBIOCIDE TAKASAGO INTERNATIONAL CORPORATION (JP) 1998-05-19 US disclosed
US-5753610-A MICROBIOCIDE TAKASAGO INTERNATIONAL CORPORATION (JP) 1998-05-19 US disclosed
EP-0731160-A3 Perfume containing (6E)-2,3-dihydrofarnesol TAKASAGO PERFUMERY CO LTD (JP) 1997-04-16 EP disclosed
EP-0754028-A1 NOVEL DEODORISING AND ANTI-MICROBIAL COMPOSITIONS FOR USE IN COSMETIC OR TOPICAL PREPARATIONS Beiersdorf Aktiengesellschaft (DE) 1997-01-22 EP disclosed
JP-H08245979-A PERFUME CONTAINING (6E)-2,3-DIHYDROFARNESOL TAKASAGO INTERNATL CORP 1996-09-24 JP disclosed
EP-0731160-A2 Perfume containing (6E)-2,3-dihydrofarnesol Takasago International Corporation (JP) 1996-09-11 EP disclosed
EP-0731160-A2 Perfume containing (6E)-2,3-dihydrofarnesol Takasago International Corporation (JP) 1996-09-11 EP disclosed
EP-0731160-A2 Perfume containing (6E)-2,3-dihydrofarnesol Takasago International Corporation (JP) 1996-09-11 EP disclosed
WO-1995026708-A2 NOVEL DEODORISING AND ANTI-MICROBIAL COMPOSITIONS FOR USE IN COSMETIC OR TOPICAL PREPARATIONS BEIERSDORF AG (DE) 1995-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11802100-B2 Olefins and methods for making the same HSD17B10, DHCR7, HSD17B12 KMT2A 2865/4885MAPT 3808/4885MEN1 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.